Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients
- 1 January 2007
- journal article
- breast cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (1), 70-76
- https://doi.org/10.1200/jco.2006.07.4393
Abstract
The incidence of venous thromboembolism (VTE) and the risk factors associated with development of VTE have not been reported in a large population-based study of breast cancer patients. The California Cancer Registry was merged with the Patient Discharge Data Set, and the number of VTE events determined among patients diagnosed between 1993 and 1999. Among 108,255 patients with breast cancer, the 2-year cumulative VTE incidence was 1.2%, with a rate of 1.2 and 0.6 events/100 patient-years during the first and second half-year, respectively. The 1-year incidence of VTE was significantly increased compared with the general population (standardized incidence ratio of VTE, 4.2; 95% CI, 3.9 to 4.4). In a multivariate model, significant predictors of developing VTE within 2 years were: age (hazard ratio [HR], 2.0 if > 75 years v < 45; 95% CI, 1.6 to 2.6), the number of chronic medical comorbidities (HR, 2.9 if 3 v 0; 95% CI, 2.4 to 3.5), and advancing cancer stage (HR, 6.3; 95% CI, 5.3 to 7.5 for metastatic v local disease). In multivariate models, VTE was a significant predictor of decreased 2-year survival (HR, 2.3; 95% CI, 2.1 to 2.6) and when stratified by initial cancer stage, the effect was highest in patients with localized (HR, 5.1; 95% CI, 3.6 to 7.1) or regional stage (HR, 3.5; 95% CI, 2.5 to 4.8) cancer compared with patients with metastatic disease (HR, 1.9; 95% CI, 1.5 to 2.4). Approximately 1% of breast cancer patients developed VTE within 2 years, with the highest incidence in the first 6 months after diagnosis. Metastatic disease and comorbidities were the strongest predictors. The diagnosis of VTE was associated with a higher risk of death within 2 years.Keywords
This publication has 29 references indexed in Scilit:
- Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on SurvivalJournal of Clinical Oncology, 2006
- Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common CancersArchives of Internal Medicine, 2006
- Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996Thrombosis and Haemostasis, 2005
- Incidence and Time Course of Thromboembolic Outcomes Following Total Hip or Knee ArthroplastyArchives of Internal Medicine, 1998
- Comorbidity Measures for Use with Administrative DataMedical Care, 1998
- Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1997
- Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.Journal of Clinical Oncology, 1996
- Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study.Journal of Clinical Oncology, 1994
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989